Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Biotechnology » HBI-4740317
  • Global Human Microbiome Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

  • Publish: April 2017 | Report Code: HBI-4740317

* For discount/customization and buying a particular chapter click here or write to us at sales@occamsresearch.com

Human microbiome is a collection of micro-organisms that resides in skin, mammary glands, placenta, uterus, seminal fluid, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, and gas intestinal tracts. Human microbiome’s main objective is to recognize and distinguish between microorganism which is associated with both healthy and diseased humans. Some pathogenic micro-organisms can harm human hosts through the metabolites they produce in the body, such as tri-methylamine. Microbiome is responsible for development and metabolic process such as brain function, food digestion and vitamin synthesis the human body. Human microbiome have a significant impact in diagnosing and treating human diseases.  Global human microbiome market is anticipated to grow with a CAGR of 21% during forecast period 2016-2023.  Growing incidences of life style diseases is the key factor for the market growth. Focus on R&D activities, participation with leading health institutions, such as International Agency for Research on Cancer (IARC) are also encouraging innovation in the market.

Microorganisms in the human body are used for the treatment of disease Lactobacillus. Probiotics are products contain live bacteria that are good for the health such as Lactobacillus. It helps to ease the symptoms of irritable bowel syndrome (IBS) in some people on consumption of dairy products. It is estimated that almost 500 to 1,000 species of bacteria are present in the human body such as Firmicutes and Bacteroidetes, Proteobacteria, Verrumicrobia, Actinobacteria, Fusobacteria. A number of bacteria such as Actinomycin viscous and A. naeslundii, present in the mouth, they are part of a sticky substance called plaque. The same bacteria secrete acids that dissolve tooth enamel, causing tooth decay. Other factors to the growth of human microbiome market are automated and advanced Instruments work on accuracy. Such as Colon Polyp and Colon Cancer Test which will introduced in the market by metabolising 2018. Moreover, the rising cases of the cardiac diseases and other disease such as obesity are expected to contribute to the growth of human Microbiome market. Excessive use of antibiotics which sometimes results in side effects on consumption is also another factor contributing to the growth of human Microbiome market. Market is expected to proliferate with in five to seven years. Lack of technical professional, lack of awareness regarding the beneficial use, lack of efforts towards research and development may be the restricting factor towards the growth of human Microbiome market.

In the present scenario, The prebiotics are acting as a key factor which are enhancing the demand which include the rising awareness considering the various crucial properties of the product such as weight loss, better digestion and lowering the risk of heart disease which results in heart attack.

Genome, Merck & Co., Vedanta Biosciences, symberix, symbiotic biotherapies, rebiotix, metabogin, Actoginics, Miomics, metabiomics,osel, ritter pharmaceuticals, avidbiotics,E.I. du Pont de Nemours and Company are some of the major players in human microbiome market. The market potential in these countries is large considering the market structure in these countries. Global human microbiome market is expected to have significant impact in diagnosing and treating diseases. Bifidobacterium is beneficial in treatment of infant diarrhoea. Microbiome market is emerging market with huge number of opportunities such as more focus on the use of probiotics and prebiotics. Vedanta Biosciences is one of the pioneer companies in human Microbiome segment field with capability to manufacture Andres archon live bacterial consortia. The European patent is an important addition to the global intellectual property portfolio of Vedanta biosciences. This is intellectual property addition put Vedanta in comfortable position to commercialize drug based on bacterial consortia. Vedanta biosciences have built a platform for the development, and manufacturing of drugs based on live commensal microbes. The Company engaged in the first large deal in the field of microbiome in a landmark licensing agreement with Johnson & Johnson with milestone payments of up to $339 million. The Company recently expanded a new headquarters and research and development facility in Cambridge USA.

 

Source: OBRC Analysis

The report is widely categorized on the basis of market segments includes products, disease and application.

 Products is further sub segmented into:

  • PROBIOTICS
  • FOODS
  • PREBIOTICS
  • MEDICAL FOODS
  • DIAGNOSTIC DEVICES
  • DRUGS
  • OTHER PROBIOTIC SUPLLEMENTS








The application segment is further sub segmented into:

  • THERAPEUTICS
  • DIAGNOSTICS



The disease segment is further sub segmented into:

  • ACUTE DIARRHOEA
  • OBESITY
  • DIABETES
  • AUTOIMMUNE DISORDER
  • CANCER
  • MENTAL DISORDER







The revenue for the above application segments are specific to the human microbiome market. However, the total revenue of these application in general has been excluded from the scope of the report. Also, the total market revenue has been calculated by summing up product segment.

Geographically, the global Human Microbiome market has been segmented on the basis of four major regions, which include:

  • North America (U.S. & Canada)
  • Asia Pacific (China, India, Japan, RoAPAC)
  • Europe (UK, France, Germany, RoE)
  • Rest of World





On the basis of Geography the market is divided into North America, Europe, and Asia–pacific, rest of the world. Europe region are the major contributor in human microbiome market with immense potential and opportunities and innovations in drug based on bacterial consortia. Additionally, changes in lifestyle of people led to increase in a number of diseases, rising aging population mainly in European countries, gradually demands of efficient and safe medication with no side effects.

The major market players of the global human microbiome market are:

  • ACTOGENIX
  • AVIDBIOTICS
  • METABIOMICS
  • METABOGEN
  • OSEL
  • IMMUNO MICROBIOME COMPANY







Why to buy the report:

This report will:

  • Provide you the business strategies adopted by market player such as Flagship Ventures announced the merger of its portfolio companies Evelo Biosciences and Epiva Biosciences to create the leading immune-microbiome company.
  • Provide in detail the different segments such as by products and end-users which are affecting the global Proteomics market.
  • Provide you the patent analysis of the Proteomics market.
  • Identify and understand the strength, opportunities, challenges and threat of the Human Microbiome market.
  • Provide revenues of major players of the market such as Symbiotic and Enterome bioscience.
  • Provide you various the regulatory policies which are affecting the global Human Microbiome market.







How we are different from others:

At Occam’s we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global human microbiome market offers the longest chain of market segmentation covering major market segmentation based on products and end users. The report tracks the major market trends in the global human microbiome market such as increasing incidences of life style diseases and so on.  For each market segments covered in global human microbiome report, we provide opportunity matrix, and DROC analysis, that enable the clear growth assessment across each market segment. The report discusses competitive landscape of the human microbiome industry, with giving extensive strategy analysis of more than 15 companies. Moreover, the report discusses various models such as 360 degree analysis, See-Saw analysis, and Porter five force model and so on. For the high level analysis in the report we provide a comparative analysis of historic and current year data. 

Key findings of the human microbiome market are as follows:

  • The factor of early detection and diagnosis of diseases in human microbiome is fuelling growth in global human microbiome market.
  • North America is anticipated to generate the largest revenue share in 2016.
  • Enhancing government support.
  • Mergers & acquisitions is the key strategy adopted by the various market players of global Human Microbiome market.
  • In 2016, Flagship Ventures announced the merger of its portfolio companies Evelo Biosciences and Epiva Biosciences to create the leading immune-microbiome company, developing therapeutics for cancer, autoimmune and inflammatory diseases.

 

1.       INTRODUCTION

1.1. EXECUTIVE SUMMARY

1.2. ESTIMATION METHODOLOGY

2.       MARKET OVERVIEW

2.1. GLOBAL HUMAN MICROBIOME MARKET: EVOLUTION AND TRANSITION

2.2. MARKET DEFINATION AND SCOPE

2.3. INDUSTRY STRUCTURE

2.4. REGULATORY FRAMEWORK

2.5. TOTAL MARKET ANALYSIS

2.5.1.        TOP 5 FINDINGS

2.5.2.        TOP 5 OPPORTUNITY MARKETS

2.5.3.        TOP 5 COMPANIES

2.5.4.        TOP 3 COMPETITIVE STRATEGIES

2.6. ESTIMATION ANALYSIS

2.7. STRATEGIC ANALYSIS

2.7.1.        INVESTMENT VS. ADOPTION MODEL

2.7.2.        360 DEGREE INDUSTRY ANALYSIS

2.7.3.        PORTERS 5 FORCE MODEL

2.7.4.        SEE-SAW ANALYSIS

2.7.5.        CONSUMER ANALYSIS AND KEY BUYING CRITERIA

2.8. COMPETITIVE ANALYSIS

2.8.1.        MARKET SHARE ANALYSIS

2.8.2.        MARKET ANALYSIS

2.8.3.        TOP COMPANY ANALYSIS

2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS

2.9.1.        INVESTMENT OPPORTUNITIES BY REGIONS

2.9.2.        OPPORTUNITIES IN EMERGING APPLICATIONS

2.9.3.        INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3.       MARKET DETERMINANTS

3.1. MARKET DRIVERS

3.1.1.        INCREASED ADOPTION OF HUMAN MICROBIOME THERAPY

3.1.2.        FOCUS  ON EARLY DISEASE DETECTION AND DIAGNOSIS

3.1.3.        GROWING TECHNOLOGICAL DRUG DEVELOPMENT

3.1.4.        USE OF HIGH VALIDATION MODEL

 

3.2. MARKET RESTRAINTS

3.1.5.        LACK OF TECHNOLOGICAL MARKET EXPERTISE

3.1.6.        LACK OF COMPREHENSIVE APPORACH

3.1.7.        BARRIERS  IN EARLY DETECTION AND DIAGNOSIS

3.1.8.        MINIMAL AWARENESS REGARDING THE BENEFICIAL USE

3.2. MARKET OPPORTUNITIES

3.2.1.        GROWING  R&D INVESTMENT

3.2.2.        INVESTMENT ON NEW DRUGS

3.2.3.        INCREASING GROWTH IN EMERGING MARKET

3.2.4.        HIGH GLOBAL OPPORTUNITIES

3.3.  MARKET CHALLENGES

3.3.1.        BARRIER FOR NEW TECHNOLOGY TO ENTER INTO MARKET

3.3.2.        STRINGENT GOVERNMENT REGULATIONS

4.       MARKET SEGMENTATION

4.1.                    GLOBAL HUMAN MICROBIOME MARKET BY PRODUCT

4.1.1.        MARKET DEFINITION AND SCOPE

4.1.2.        DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.1.3.        COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.1.4.        OPPORTUNITY MATRIX

4.1.5.        MARKET SEGMENTATION

4.1.5.1.                      BY PROBIOTICS

4.1.5.1.1.         APPLICATIONS

4.1.5.1.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.1.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.1.5.1.4.         TOP PLAYERS & KEY PRODUCTS

4.1.5.1.5.         KEY CONCLUSIONS

4.1.5.2.                      BY FOODS 

4.1.5.2.1.         APPLICATIONS

4.1.5.2.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.2.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.1.5.2.4.         TOP PLAYERS & KEY PRODUCTS

4.1.5.2.5.         KEY CONCLUSIONS

4.1.5.3.                      BY PREBIOTICS

4.1.5.3.1.         APPLICATIONS

4.1.5.3.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.3.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.3.4.         TOP PLAYERS & KEY PRODUCTS

4.1.5.3.5.         KEY CONCLUSIONS

4.1.5.4.                      BY MEDICAL FOODS

4.1.5.4.1.          APPLICATIONS

4.1.5.4.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.4.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.4.4.         TOP PLAYERS & KEY PRODUCTS

4.1.5.4.5.         KEY CONCLUSIONS

4.1.5.5.                      BY DIAGNOSTIC DEVICES

4.1.5.5.1.         APPLICATIONS

4.1.5.5.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.5.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.5.4.         TOP PLAYERS & KEY PRODUCTS

4.1.5.5.5.         KEY CONCLUSIONS

4.1.5.6.                      BY DRUGS

4.1.5.6.1.         APPLICATIONS

4.1.5.6.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.6.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.6.4.         TOP PLAYERS & KEY PRODUCTS

4.1.5.6.5.         KEY CONCLUSIONS

4.1.5.7.                      BY OTHER PROBIOTIC SUPPLEMENTS

4.1.5.7.1.          APPLICATIONS

4.1.5.7.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.7.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.7.4.         TOP PLAYERS & KEY PRODUCTS

4.1.5.7.5.         KEY CONCLUSIONS

4.2. GLOBAL HUMAN MICROBIOME MARKET BY APPLICATION

4.2.1.        MARKET DEFINITION AND SCOPE

4.2.2.        DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.2.3.        COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.2.4.         OPPORTUNITY MATRIX

4.2.5.        MARKET SEGMENTATION 2014-2023($ MILLION)

4.2.5.1.                       THERAPEUTICS

4.2.5.1.1.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.1.2.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.2.5.1.3.         TOP PLAYERS & KEY PRODUCTS

4.2.5.1.4.         KEY CONCLUSIONS

4.2.5.2.                      DIAGNOSTICS

4.2.5.2.1.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.2.2.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.2.5.2.3.         TOP PLAYERS & KEY PRODUCTS

4.2.5.2.4.         KEY CONCLUSIONS

4.3.                    GLOBAL HUMAN MICROBIOME MARKET BY DISEASE

4.3.1.        MARKET DEFINITION AND SCOPE

4.3.2.        DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.3.3.        COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.3.4.         OPPORTUNITY MATRIX

4.3.5.        MARKET SEGMENTATION

4.3.5.1.                      ACUTE DIARRHEA 

4.3.5.1.1.          APPLICATIONS

4.3.5.1.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.1.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.3.5.1.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.1.5.         KEY CONCLUSIONS

4.3.5.2.                        OBESITY 

4.3.5.2.1.         APPLICATIONS

4.3.5.2.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.2.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.3.5.2.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.2.5.         KEY CONCLUSIONS

4.3.5.3.                           DIABETES 

4.3.5.3.1.          APPLICATIONS

4.3.5.3.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.3.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.3.5.3.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.3.5.         KEY CONCLUSIONS

4.3.5.4.                      AUTOIMMUNE DISORDER      

4.3.5.4.1.          APPLICATIONS

4.3.5.4.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.4.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.3.5.4.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.4.5.         KEY CONCLUSIONS

4.3.5.5.                      CANCER

4.3.5.5.1.         APPLICATIONS

4.3.5.5.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.5.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.3.5.5.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.5.5.         KEY CONCLUSIONS

4.3.5.6.                      MENTAL DISORDER

4.3.5.6.1.         APPLICATIONS

4.3.5.6.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.6.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

4.3.5.6.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.6.5.         KEY CONCLUSIONS

 

 

5.       COMPETITIVE LANDSCAPE

5.1. KEY STRATEGIES

5.1.1.        LIST OF M&A

5.1.2.        LIST OF JV

5.1.3.        LIST OF PRODUCT LAUNCHES

5.1.4.        LIST OF PARTNERSHIP

5.2. TOP 10 COMPANY ANALYSIS

6.      GLOBAL   HUMAN MICROBIOME MARKET BY REGION 2014-2023 ($MILLION)

6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

6.3. OPPORTUNITY MATRIX

6.4. GEOGRAPHIC SEGMENTATION

6.4.1.     NORTH AMERICA

6.4.1.1.  INDUSTRIAL APPLICATION ANALYSIS

6.4.1.2.  TOP COUNTRY ANALYSIS

6.4.1.2.1.    U.S.

6.4.1.2.1.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.1.2.1.2.   TOP PLAYERS & KEY PRODUCTS

6.4.1.2.1.3.   KEY CONCLUSIONS

6.4.1.2.2.    CANADA

6.4.1.2.2.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.1.2.2.2.   TOP PLAYERS & KEY PRODUCTS

6.4.1.2.2.3.   KEY CONCLUSIONS

6.4.2.     EUROPE

6.4.2.1.  INDUSTRY APPLICATION ANALYSIS 2014-2023 ($ MILLION)

6.4.2.2.  TOP COUNTRY ANALYSIS

6.4.2.2.1.    UK

6.4.2.2.1.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.1.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.1.3.   KEY CONCLUSIONS

6.4.2.2.2.    GERMANY

6.4.2.2.2.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.2.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.2.3.   KEY CONCLUSIONS

6.4.2.2.3.    SPAIN

6.4.2.2.3.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.3.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.3.3.   KEY CONCLUSIONS

6.4.2.2.4.    ITALY

6.4.2.2.4.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.4.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.4.3.   KEY CONCLUSIONS

6.4.2.2.5.    FRANCE

6.4.2.2.5.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.5.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.5.3.   KEY CONCLUSIONS

6.4.2.2.6.    REST OF EUROPE

6.4.2.2.6.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.6.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.6.3.   KEY CONCLUSIONS

6.4.3.     ASIA PACIFIC

6.4.3.1.  INDUSTRY APPLICATION ANALYSIS 2014-2023 ($ MILLION)

6.4.3.2.  TOP COUNTRY ANALYSIS

6.4.3.2.1.    CHINA

6.4.3.2.1.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.1.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.1.3.   KEY CONCLUSIONS

6.4.3.2.2.    INDIA

6.4.3.2.2.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.2.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.2.3.   KEY CONCLUSIONS

6.4.3.2.3.    JAPAN

6.4.3.2.3.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.3.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.3.3.   KEY CONCLUSIONS

6.4.3.2.4.    SOUTH KOREA

6.4.3.2.4.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.4.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.4.3.   KEY CONCLUSIONS

6.4.3.2.5.    AUSTRALIA

6.4.3.2.5.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.5.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.5.3.   KEY CONCLUSIONS

6.4.3.2.6.    REST OF ASIA PACIFIC

6.4.3.2.6.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.6.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.6.3.   KEY CONCLUSIONS

6.4.4.     ROW

6.4.4.1.  INDUSTRY APPLICATION ANALYSIS 2014-2023 ($ MILLION)

6.4.4.2.  TOP COUNTRY ANALYSIS

6.4.4.2.1.    LATIN AMERICA

6.4.4.2.1.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.4.2.1.2.   TOP PLAYERS & KEY PRODUCTS

6.4.4.2.1.3.   KEY CONCLUSIONS

6.4.4.2.2.    MIDDLE EAST & AFRICA

6.4.4.2.2.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)

6.4.4.2.2.2.   TOP PLAYERS & KEY PRODUCTS

6.4.4.2.2.3.   KEY CONCLUSIONS

7.       COMPANY PROFILES

7.1.1.        ACTOGENIX

7.1.1.1.  OVERVIEW

7.1.1.2.  PRODUCT PORTFOLIO

7.1.1.3.  KEY INOVATION SECTOR

7.1.1.4.  STRATEGIC INITIATIVES

7.1.1.5.  SCOT ANALYSIS

7.1.1.6.  STRATEGIC ANALYSIS

7.2.  AVIDBIOTICS

7.2.1.        OVERVIEW

7.2.2.        PRODUCT PORTFOLIO

7.2.3.        KEY INOVATION SECTOR

7.2.4.        STRATEGIC INITIATIVES

7.2.5.        SCOT ANALYSIS

7.2.6.         

7.3.   ENTEROLOGICS

7.3.1.        OVERVIEW

7.3.2.        PRODUCT PORTFOLIO

7.3.3.        KEY INOVATION SECTOR

7.3.4.        STRATEGIC INITIATIVES

7.3.5.        SCOT ANALYSIS

7.3.6.        STRATEGIC  ANALYSIS

7.4.   ENTEROME BIOSCIENCE

7.4.1.        OVERVIEW

7.4.2.        PRODUCT PORTFOLIO

7.4.3.        KEY INOVATION SECTOR

7.4.4.        STRATEGIC INITIATIVES

7.4.5.        SCOT ANALYSIS

7.4.6.        STRATEGIC  ANALYSIS

7.5.   METABIOMICS

7.5.1.        OVERVIEW

7.5.2.        PRODUCT PORTFOLIO

7.5.3.        KEY INOVATION SECTOR

7.5.4.        STRATEGIC INITIATIVES

7.5.5.        SCOT ANALYSIS

7.5.6.        STRATEGIC  ANALYSIS

7.6.    MICROBIOME THERAPEUTICS LLC

7.6.1.        OVERVIEW

7.6.2.        PRODUCT PORTFOLIO

7.6.3.        KEY INOVATION SECTOR

7.6.4.        STRATEGIC INITIATIVES

7.6.5.        SCOT ANALYSIS

7.6.6.        STRATEGIC  ANALYSIS

7.7.  METABOGEN

7.7.1.        OVERVIEW

7.7.2.        PRODUCT PORTFOLIO

7.7.3.        KEY INOVATION SECTOR

7.7.4.        STRATEGIC INITIATIVES

7.7.5.        SCOT ANALYSIS

7.7.6.        STRATEGIC  ANALYSIS

7.8.   MIOMICS

7.8.1.        OVERVIEW

7.8.2.        PRODUCT PORTFOLIO

7.8.3.        KEY INOVATION SECTOR

7.8.4.        STRATEGIC INITIATIVES

7.8.5.        SCOT ANALYSIS

7.8.6.        STRATEGIC  ANALYSIS

7.9.  OSEL

7.9.1.        OVERVIEW

7.9.2.        PRODUCT PORTFOLIO

7.9.3.        KEY INOVATION SECTOR

7.9.4.        STRATEGIC INITIATIVES

7.9.5.        SCOT ANALYSIS

7.9.6.        STRATEGIC  ANALYSIS

7.10.                     REBIOTIX

7.10.1.    OVERVIEW

7.10.2.    PRODUCT PORTFOLIO

7.10.3.    KEY INOVATION SECTOR

7.10.4.    STRATEGIC INITIATIVES

7.10.5.    SCOT ANALYSIS

7.10.6.    STRATEGIC  ANALYSIS

7.11.                    RITTER PHARMACEUTICALS

7.11.1.    OVERVIEW

7.11.2.    PRODUCT PORTFOLIO

7.11.3.    KEY INOVATION SECTOR

7.11.4.    STRATEGIC INITIATIVES

7.11.5.    SCOT ANALYSIS

7.11.6.    STRATEGIC  ANALYSIS

7.12.                  SECOND GENOME 

7.12.1.    OVERVIEW

7.12.2.    PRODUCT PORTFOLIO

7.12.3.    KEY INOVATION SECTOR

7.12.4.    STRATEGIC INITIATIVES

7.12.5.    SCOT ANALYSIS

7.12.6.    STRATEGIC  ANALYSIS 

7.13.                  SYMBERIX

7.13.1.    OVERVIEW

7.13.2.    PRODUCT PORTFOLIO

7.13.3.    KEY INOVATION SECTOR

7.13.4.    STRATEGIC INITIATIVES

7.13.5.    SCOT ANALYSIS

7.13.6.    STRATEGIC  ANALYSIS

7.14.                  SYMBIOTIX  BIOTHERAPICS

7.14.1.    OVERVIEW

7.14.2.    PRODUCT PORTFOLIO

7.14.3.    KEY INOVATION SECTOR

7.14.4.    STRATEGIC INITIATIVES

7.14.5.    SCOT ANALYSIS

7.14.6.    STRATEGIC  ANALYSIS

7.15.                  VEDANTA

7.15.1.    OVERVIEW

7.15.2.    PRODUCT PORTFOLIO

7.15.3.    KEY INOVATION SECTOR

7.15.4.    STRATEGIC INITIATIVES

7.15.5.    SCOT ANALYSIS

7.15.6.    STRATEGIC  ANALYSIS

LIST OF TABLES

 

1.            GLOBAL HUMAN MICROBIOME MARKET BY PRODUCT 2014-2023 ($ MILLION)

2.            GLOBAL PROBIOTICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($MILLION)

3.            GLOBAL FOODS HUMAN MICROBIOME MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)

4.            GLOBAL PREBIOTICS HUMAN MICROBIOME MARKET  BY GEOGRAPHY 2014-2023($ MILLION)

5.            GLOBAL MEDICAL FOODS HUMAN MICROBIOME MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)

6.            GLOBAL DRUGS HUMAN MICROBIOME MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)

7.            GLOBAL DIAGNOSTICS DEVICES HUMAN MICROBIOME MARKET  GEOGRAPHY 2014-2023 ($ MILLION)

8.            GLOBAL BY OTHER PROBIOTICS SUPPLEMENTS HUMAN MICROBIOME MARKET   GEOGRAPHY 2014-2023 ($ MILLION)

9.            GLOBAL HUMAN MICROBIOME MARKET BY APPLICATION 2014-2023 ($ MILLION)

10.        GLOBAL  THERAPEUTICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

11.        GLOBAL DIAGNOSTICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

12.        GLOBAL HUMAN MICROBIOME MARKET BY DISEASE 2014-2023 ($ MILLION)

13.        GLOBAL ACUTE DIARRHEA HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

14.        GLOBAL  OBESITY HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

15.        GLOBAL DIABETICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

16.        GLOBAL CANCER HUMAN MICROBIOME MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)

17.        GLOBAL AUTOIMMUNE DISORDER HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

18.        GLOBAL MENTAL DISORDER HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

19.        NORTH AMERICA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

20.        EUROPE HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)20

21.        ASIA PACIFIC HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

22.        REST OF THE WORLD HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

LIST OF FIGURES

1.       GLOBAL HUMAN MICROBIOME MARKET  BY FOOD 2014-2023 ($ MILLION)

2.       GLOBAL HUMAN MICROBIOME MARKET  PROBIOTICS 2014-2023 ($ MILLION)

3.       GLOBAL HUMAN MICROBIOME MARKET  PREBIOTICS 2014-2023 ($ MILLION)

4.       GLOBAL HUMAN MICROBIOME MARKET  MEDICAL FOODS  2014-2023 ($ MILLION)

5.       GLOBAL HUMAN MICROBIOME MARKET  DIAGNOSTIC DEVICES 2014-2023 ($ MILLION)

6.       GLOBAL HUMAN MICROBIOME MARKET  DRUGS 2014-2023 ($ MILLION)

7.       GLOBAL HUMAN MICROBIOME MARKET  OTHER PROBIOTICS SUPPLEMENT 2014-2023 ($ MILLION)

8.       GLOBAL HUMAN MICROBIOME MARKET  THERAPEUTICS 2014-2023 ($ MILLION)

9.       GLOBAL HUMAN MICROBIOME MARKET  DIAGNOSTICS 2014-2023 ($ MILLION)

10.   GLOBAL HUMAN MICROBIOME MARKET  ACUTE DIARRHEA 2014-2023 ($ MILLION)

11.   GLOBAL HUMAN MICROBIOME MARKET  OBESITY 2014-2023 ($ MILLION)

12.   GLOBAL HUMAN MICROBIOME MARKET    DIABETICS 2014-2023 ($ MILLION)

13.   GLOBAL HUMAN MICROBIOME MARKET  CANCER 2014-2023 ($ MILLION)

14.   GLOBAL HUMAN MICROBIOME MARKET  AUTOIMMUNE DISORDER 2014-2023 ($ MILLION)

15.   GLOBAL HUMAN MICROBIOME MARKET  MENTAL DISORDER 2014-2023 ($ MILLION)

16.   UNITED STATES (U.S.) HUMAN MICROBIOME MARKET2014-2023 ($ MILLION)

17.   CANADA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

18.   UNITED KINGDOM (UK) HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

19.   GERMANY HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

20.   SPAIN HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

21.   ITALY HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

22.   FRANCE HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

23.   ROE HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

24.   INDIA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

25.   CHINA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

26.   JAPAN HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

27.   KOREA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

28.   ROWAPAC HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

29.   LATIN AMERICA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

30.   MENA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample


UPCOMING REPORTS

No upcoming reports available under this subcategory.
credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 9713031393

Email: info@occamsresearch.com

 

 

Go To Top
viewthroughconversion